GeneDx Holdings Faces Securities Class Action Investigation Over Fabric Genomics Impairment
WGS has more than doubled off its 52-week low of $32.21.
Summary
Hagens Berman has launched a securities class action investigation against GeneDx Holdings and its executives. The lawsuit alleges the company misled investors regarding its Fabric Genomics acquisition and its synergy potential. This follows GeneDx's Q1 2026 earnings report on May 4, which revealed a $31.2 million impairment charge related to Fabric Genomics and a significant cut to 2026 revenue guidance, causing a 49% stock decline. The investigation adds substantial legal and financial risk for the company. The lead plaintiff deadline for the class action is August 3, 2026.
At the time of this announcement, WGS was trading at $69.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: PR Newswire.